Overview

Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The study aims to determine whether the infusion of DEX in septic shock can reduce in-hospital mortality, norepinephrine infusion, need and duration for mechanical ventilation, and acute kidney injury without significant adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
Mansoura University
Treatments:
Dexmedetomidine